DDInter392 DDInter1607
An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia.
Ritonavir is an HIV protease inhibitor that interferes with the reproductive cycle of HIV. Although it was initially developed as an independent antiviral agent, it has been shown to possess advantageous properties in combination regimens with low-dose ritonavir and other protease inhibitors. It is now more commonly used as a booster of other protease inhibitors and is available in both liquid formulations and as capsules. While ritonavir is not an active antiviral agent against hepatitis C virus (HCV) infection, it is added in combination therapies indicated for the treatment of HCV infections as a booster. Ritonavir is a potent CYP3A inhibitor that increases peak and trough plasma drug concentrations of other protease inhibitors such as and overall drug exposure. American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) guidelines recommend ritonavir-boosted combination therapies as first-line therapy for HCV Genotype 1a/b and 4 treatment-naïve patients with or without cirrhosis. Ritonavir is found in a fixed-dose combination product with , , and as the FDA-approved product Viekira Pak. First approved in December 2014, Viekira Pak is indicated for the treatment of HCV genotype 1b without cirrhosis or with compensated cirrhosis, and when combined with Ribavirin for the treatment of HCV genotype 1a without cirrhosis or with compensated cirrhosis. Ritonavir is also available as a fixed-dose combination product with and as the FDA- and Health Canada-approved product Technivie. First approved in July 2015, Technivie is indicated in combination with Ribavirin for the treatment of patients with genotype 4 chronic hepatitis C virus (HCV) infection without cirrhosis or with compensated cirrhosis. In Canada, ritonavir is also available as a fixed-dose combination product with , , and as the Health Canada-approved, commercially available product Holkira Pak. First approved in January 2015, Holkira Pak is indicated for the treatment of HCV genotype 1b with or without cirrhosis, and when combined with Ribavirin for the treatment of HCV genotype 1a with or without cirrhosis. The inclusion of ritonavir can select for HIV-1 protease inhibitor resistance-associated substitutions. Any HCV/HIV-1 co-infected patients treated with ritonavir-containing combination therapies should also be on a suppressive antiretroviral drug regimen to reduce the risk of HIV-1 protease inhibitor drug resistance. Ritonavir is combined with other drugs to treat coronavirus disease 2019 (COVID-19) in patients at risk for progressing into a severe form of the disease, such as [nirmatrelvir].
Cladribine {u} may lead to a major life threatening interaction when taken with {v} Carfilzomib
Carfilzomib {u} (Compound) resembles {v} (Compound) Ritonavir
Cladribine {u} (Compound) binds {v} (Gene) ABCG2
ABCG2 {u} (Gene) is bound by {v} (Compound) Ritonavir
Cladribine {u} (Compound) downregulates {v} (Gene) VPS28
VPS28 {u} (Gene) is downregulated by {v} (Compound) Ritonavir
Cladribine {u} (Compound) causes {v} (Side Effect) Epistaxis
Epistaxis {u} (Side Effect) is caused by {v} (Compound) Ritonavir
Cladribine {u} may lead to a major life threatening interaction when taken with {v} Carfilzomib
Carfilzomib {u} (Compound) resembles {v} (Compound) Lopinavir
Lopinavir {u} (Compound) resembles {v} (Compound) Ritonavir
Cladribine {u} (Compound) binds {v} (Gene) ABCG2
ABCG2 {u} (Gene) regulates {v} (Gene) AGR2
AGR2 {u} (Gene) is upregulated by {v} (Compound) Ritonavir
Cladribine {u} (Compound) causes {v} (Side Effect) Connective tissue disorder
Connective tissue disorder {u} (Side Effect) is caused by {v} (Compound) Atazanavir
Atazanavir {u} (Compound) resembles {v} (Compound) Ritonavir
Cladribine {u} may lead to a major life threatening interaction when taken with {v} Carfilzomib
Carfilzomib {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Ritonavir
Cladribine {u} may lead to a major life threatening interaction when taken with {v} Carfilzomib
Carfilzomib {u} (Compound) causes {v} (Side Effect) Chills
Chills {u} (Side Effect) is caused by {v} (Compound) Ritonavir
Cladribine {u} may lead to a major life threatening interaction when taken with {v} Ciclesonide
Ciclesonide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Atazanavir
Atazanavir {u} (Compound) resembles {v} (Compound) Ritonavir
Cladribine may lead to a major life threatening interaction when taken with Carfilzomib and Carfilzomib (Compound) resembles Ritonavir (Compound)
Cladribine (Compound) binds ABCG2 (Gene) and ABCG2 (Gene) is bound by Ritonavir (Compound)
Cladribine (Compound) downregulates VPS28 (Gene) and VPS28 (Gene) is downregulated by Ritonavir (Compound)
Cladribine (Compound) causes Epistaxis (Side Effect) and Epistaxis (Side Effect) is caused by Ritonavir (Compound)
Cladribine may lead to a major life threatening interaction when taken with Carfilzomib and Carfilzomib (Compound) resembles Lopinavir (Compound) and Lopinavir (Compound) resembles Ritonavir (Compound)
Cladribine (Compound) binds ABCG2 (Gene) and ABCG2 (Gene) regulates AGR2 (Gene) and AGR2 (Gene) is upregulated by Ritonavir (Compound)
Cladribine (Compound) causes Connective tissue disorder (Side Effect) and Connective tissue disorder (Side Effect) is caused by Atazanavir (Compound) and Atazanavir (Compound) resembles Ritonavir (Compound)
Cladribine may lead to a major life threatening interaction when taken with Carfilzomib and Carfilzomib (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Ritonavir (Compound)
Cladribine may lead to a major life threatening interaction when taken with Carfilzomib and Carfilzomib (Compound) causes Chills (Side Effect) and Chills (Side Effect) is caused by Ritonavir (Compound)
Cladribine may lead to a major life threatening interaction when taken with Ciclesonide and Ciclesonide may cause a moderate interaction that could exacerbate diseases when taken with Atazanavir and Atazanavir (Compound) resembles Ritonavir (Compound)